Gigliola Di Matteo

Dr. Gigliola Di Matteo

Tor Vergata University Rome Italy, Department of System Medicine
+1

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
DRDirk Roos
Dirk Roos
DKDouglas B. Kuhns
Douglas B. Kuhns
AMAnne Maddalena
Anne Maddalena
JRJoachim Roesler
Joachim Roesler
JLJuan Alvaro Lopez
Juan Alvaro Lopez
JGJohn I. Gallin
John I. Gallin

8 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MSMehul Sharma
Mehul Sharma
DLDaniel Leung
Daniel Leung
MMMana Momenilandi
Mana Momenilandi
LJLauren C.W. Jones
Lauren C.W. Jones
LPLucia Pacillo
Lucia Pacillo
STStuart E. Turvey
Stuart E. Turvey
STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti–IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder.

21 January 2016 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MCMaria Chiriaco
Maria Chiriaco
ISIrene Salfa
Irene Salfa
GMGigliola Di Matteo
Gigliola Di Matteo
Pier Paolo RossiPier Paolo Rossi
Pier Paolo Rossi
AFAndrea Finocchi
Andrea Finocchi

1 July 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
JFJocelyn R. Farmer
Jocelyn R. Farmer
ZFZsofia Foldvari
Zsofia Foldvari
BUBoglarka Ujhazi
Boglarka Ujhazi
SRSuk See De Ravin
Suk See De Ravin
KCKarin Chen
Karin Chen
JWJolan E Walter
Jolan E Walter
Although autoimmunity and hyperinflammation secondary to recombination activating gene (RAG) deficiency have been associated with delayed diagnosis and even death, our current understanding is limited primarily to small case series. Understand the frequency, severity, and treatment responsiveness of autoimmunity and hyperinflammation in RAG deficiency. In reviewing the literature and our own database, we identified 85 patients with RAG deficiency, reported between 2001 and 2016, and compiled the largest case series to date of 63 patients with prominent autoimmune and/or hyperinflammatory pathology. Diagnosis of RAG deficiency was delayed a median of 5 years from the first clinical signs of immune dysregulation. Most patients (55.6%) presented with more than 1 autoimmune or hyperinflammatory complication, with the most common etiologies being cytopenias (84.1%), granulomas (23.8%), and inflammatory skin disorders (19.0%). Infections, including live viral vaccinations, closely preceded the onset of autoimmunity in 28.6% of cases. Autoimmune cytopenias had early onset (median, 1.9, 2.1, and 2.6 years for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively) and were refractory to intravenous immunoglobulin, steroids, and rituximab in most cases (64.7%, 73.7%, and 71.4% for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively). Evans syndrome specifically was associated with lack of response to first-line therapy. Treatment-refractory autoimmunity/hyperinflammation prompted hematopoietic stem cell transplantation in 20 patients. Autoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should prompt further evaluation. Multilineage cytopenias are often refractory to immunosuppressive treatment and may require hematopoietic cell transplantation for definitive management.

17 July 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
KDKerry Dobbs
Kerry Dobbs
GTGiovanna Tabellini
Giovanna Tabellini
ECEnrica Calzoni
Enrica Calzoni
OPOrnella Patrizi
Ornella Patrizi
PMPaula Martinez
Paula Martinez
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Mutations of the recombinase Activating Genes 1 and 2 (RAG1, RAG2) in humans are associated with a broad range of phenotypes. For patients with severe clinical presentation, hematopoietic stem cell transplantation (HSCT) represents the only curative treatment, however high rates of graft failure and incomplete immune reconstitution have been observed, especially after unconditioned haploidentical transplantation. Studies in mice have shown that Rag-/- NK cells have a mature phenotype, reduced fitness and increased cytotoxicity. We aimed to analyze NK cell phenotype and function in patients with mutations in RAG and in non-homologous end joining (NHEJ) genes. Here we provide evidence that NK cells from these patients have an immature phenotype, with significant expansion of CD56bright CD16-/int CD57- cells, yet increased degranulation and high perforin content. Correlation was observed between in vitro recombinase activity of the mutant proteins, NK cell abnormalities, and in vivo clinical phenotype. Addition of serotherapy in the conditioning regimen, with the aim of depleting the autologous NK cell compartment, may be important to facilitate engraftment and immune reconstitution in patients with RAG and NHEJ defects treated by HSCT.

1 August 2014 in Molecular Therapy
Verified
Journal Article
Open access
MCMaria Chiriaco
Maria Chiriaco
GFGiada Farinelli
Giada Farinelli
VCValentina Capo
Valentina Capo
EZErika Zonari
Erika Zonari
SSSamantha Scaramuzza
Samantha Scaramuzza
AAAlessandro Aiuti
Alessandro Aiuti
Regulated transgene expression may improve the safety and efficacy of hematopoietic stem cell (HSC) gene therapy. Clinical trials for X-linked chronic granulomatous disease (X-CGD) employing gammaretroviral vectors were limited by insertional oncogenesis or lack of persistent engraftment. Our novel strategy, based on regulated lentiviral vectors (LV), targets gp91(phox) expression to the differentiated myeloid compartment while sparing HSC, to reduce the risk of genotoxicity and potential perturbation of reactive oxygen species levels. Targeting was obtained by a myeloid-specific promoter (MSP) and posttranscriptional, microRNA-mediated regulation. We optimized both components in human bone marrow (BM) HSC and their differentiated progeny in vitro and in a xenotransplantation model, and generated therapeutic gp91(phox) expressing LVs for CGD gene therapy. All vectors restored gp91(phox) expression and function in human X-CGD myeloid cell lines, primary monocytes, and differentiated myeloid cells. While unregulated LVs ectopically expressed gp91(phox) in CD34(+) cells, transcriptionally and posttranscriptionally regulated LVs substantially reduced this off-target expression. X-CGD mice transplanted with transduced HSC restored gp91(phox) expression, and MSP-driven vectors maintained regulation during BM development. Combining transcriptional (SP146.gp91-driven) and posttranscriptional (miR-126-restricted) targeting, we achieved high levels of myeloid-specific transgene expression, entirely sparing the CD34(+) HSC compartment. This dual-targeted LV construct represents a promising candidate for further clinical development.